Copenhagen, 31 August 2009 - NeuroSearch (NEUR) will make a presentation at the
11th Rodman & Renshaw Annual Healthcare Conference to be held on 9-11 September
at the New York Palace Hotel, New York.


NeuroSearch's presentation is scheduled for:

Friday, 11 September at 11:40 am to 12:05 pm local time

and will be held by CEO Flemming Pedersen.


In his presentation, Flemming Pedersen will give an update on NeuroSearch's
broad clinical pipeline with focus on HuntexilTM (pridopidine), a Phase III
orphan drug for the treatment of Huntington's disease, and tesofensine, a novel
anti-obesity product ready for Phase III development as well as on the
company's new CNS focused drug discovery and development alliances with Eli
Lilly and Janssen.

The presentation will be webcasted and the link to access the audio webcast
will be available at www.neurosearch.com together with the powerpoint
presentation just before the presentation will be held at the conference.


Contact person:

Hanne Leth Hillman, Vice President, Director of Investor & Capital Market
Relations, telephone: +45 4017 5103


About NeuroSearch
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on NASDAQ
OMX Copenhagen. The core business of the company covers the development of
novel pharmaceutical agents, based on a broad and well-established drug
discovery platform focusing on ion channels and central nervous system (CNS)
disorders. A substantial share of the activities is partner financed through
strategic alliances with Janssen Pharmaceutica, Eli Lilly and Company and
GlaxoSmithKline (GSK), and license collaboration with Abbott. The drug pipeline
comprises seven clinical (Phase I-III) development programmes: Pridopidine
(ACR16) for Huntington's disease (Phase III), tesofensine for obesity (Phase
III ready), ABT-894 for ADHD (Phase II) in partnership with Abbott, ACR343 for
schizophrenia (Phase II ready), ACR325 to treat dyskinesias in Parkinson's
disease (Phase Ib), ABT-560 for the treatment of cognitive dysfunctions (Phase
I) in collaboration with Abbott, NSD-788 for anxiety (Phase I) and NSD-721 for
social anxiety disorder (Phase I). In addition, NeuroSearch has a broad
portfolio of preclinical drug candidates and holds equity interests in several
biotech companies.

presse.10-09 - rodman & renshaw 11th annual healthcare conference - uk.pdf